loader
Please Wait
Applying Filters...

Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Olinciguat, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Olinciguat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Bora Pharmaceuticals- Making success more certain.

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    2D Structure
    1. Also known as: 1628732-62-6, Olinciguat [inn], Iw-1701, Olinciguat [usan], Iw1701, Pd5f4zxd21
    Molecular Formula
    C21H16F5N7O3
    Molecular Weight
    509.4  g/mol
    InChI Key
    YWQFJNWMWZMXRW-HXUWFJFHSA-N
    FDA UNII
    PD5F4ZXD21
    Olinciguat is an orally bioavailable stimulator of soluble guanylate cyclase (sGC), with potential anti-inflammatory and vasodilating activities. Upon oral administration, olinciguat targets, allosterically binds to and enhances the nitric oxide (NO)-dependent catalytic activity of sGC. This enhances NO-sGC signaling and increases the formation of the intracellular second messenger cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). This enhances NO/cGMP-mediated muscle relaxation, suppresses leukocyte-endothelial interactions and promotes vascular anti-inflammatory effects. The NO/sGC/cGMP signaling pathway plays an important role in vasodilation, blood flow and inflammatory processes. sGC, a heme-containing cytoplasmic signaling enzyme, catalyzes the formation of cGMP from GTP in response to NO binding to heme.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide
    2.1.2 InChI
    InChI=1S/C21H16F5N7O3/c22-12-4-2-1-3-11(12)9-33-16(14-5-6-36-32-14)7-15(31-33)18-28-8-13(23)17(30-18)29-10-20(35,19(27)34)21(24,25)26/h1-8,35H,9-10H2,(H2,27,34)(H,28,29,30)/t20-/m1/s1
    2.1.3 InChI Key
    YWQFJNWMWZMXRW-HXUWFJFHSA-N
    2.1.4 Canonical SMILES
    C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NCC(C(=O)N)(C(F)(F)F)O)F)C4=NOC=C4)F
    2.1.5 Isomeric SMILES
    C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NC[C@@](C(=O)N)(C(F)(F)F)O)F)C4=NOC=C4)F
    2.2 Other Identifiers
    2.2.1 UNII
    PD5F4ZXD21
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 1628732-62-6

    2. Olinciguat [inn]

    3. Iw-1701

    4. Olinciguat [usan]

    5. Iw1701

    6. Pd5f4zxd21

    7. (2r)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide

    8. Olinciguat (usan/inn)

    9. Olinciguat [usan:inn]

    10. Unii-pd5f4zxd21

    11. Olinciguat [who-dd]

    12. Chembl4297616

    13. Schembl16081945

    14. Gtpl10213

    15. Bdbm321744

    16. Db15238

    17. Iw-1701iw-1701

    18. Us10183021, Compound I-531

    19. Ac-31551

    20. Hy-109066

    21. Cs-0033431

    22. D11475

    23. D87219

    24. (2~{r})-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide

    25. (2r)-3,3,3-trifluoro-2-(((5-fluoro-2-(1-((2-fluorophenyl)methyl)-5-(1,2-oxazol-3-yl)-1h-pyrazol-3-yl)pyrimidin-4-yl)amino)methyl)-2-hydroxypropanamide

    26. Propanamide, 3,3,3-trifluoro-2-(((5-fluoro-2-(1-((2-fluorophenyl)methyl)-5-(3-isoxazolyl)-1h-pyrazol-3-yl)-4-pyrimidinyl)amino)methyl)-2-hydroxy-, (2r)-

    2.4 Create Date
    2015-02-13
    3 Chemical and Physical Properties
    Molecular Weight 509.4 g/mol
    Molecular Formula C21H16F5N7O3
    XLogP32.3
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count13
    Rotatable Bond Count8
    Exact Mass509.12347821 g/mol
    Monoisotopic Mass509.12347821 g/mol
    Topological Polar Surface Area145 Ų
    Heavy Atom Count36
    Formal Charge0
    Complexity768
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of sickle cell disease

    Post Enquiry
    POST ENQUIRY